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Objectives: Meropenem is frequently used to treat pulmonary exacerbations in children with cystic fibrosis (CF) in
the USA. Prolonged-infusion meropenem improves the time that free drug concentrations remain above the MIC
(fT.MIC) in adults, but data in CF children are sparse. We describe the population pharmacokinetics, tolerability
and treatment burden of prolonged-infusion meropenem in CF children.
Methods: Thirty children aged 6–17 years with a pulmonary exacerbation received 40 mg/kg meropenem every
8 h; each dose was administered as a 3 h infusion. Pharmacokinetics were determined using population methods
in Pmetrics. Monte Carlo simulation was employed to compare 0.5 with 3 h infusions to estimate the probability
of pharmacodynamic target attainment (PTA) at 40% fT.MIC. NCT#01429259.
Results: A two-compartment model fitted the data best with clearance and volume predicted by body weight.
Clearance and volume of the central compartment were 0.41+0.23 L/h/kg and 0.30+0.17 L/kg, respectively.
Half-life was 1.11+0.38 h. At MICs of 1, 2 and 4 mg/L, PTAs for the 0.5 h infusion were 87.6%, 70.1% and
35.4%, respectively. The prolonged infusion increased PTAs to .99% for these MICs and achieved 82.8% at
8 mg/L. Of the 30 children, 18 (60%) completed treatment with prolonged infusion; 5 did so at home without
any reported burden. Nine patients were changed to a 0.5 h infusion when discharged home.
Conclusions: In these CF children, meropenem clearance was greater compared with published values from non-
CF children. Prolonged infusion provided an exposure benefit against pathogens with MICs ≥1 mg/L, was well
tolerated and was feasible to administer in the hospital and home settings, the latter depending on perception
and family schedule.
Introduction
While cystic fibrosis (CF) is a multi-organ disease, it is the decline in
pulmonary function as a result of chronic infection and inflamma-
tion that results in significant morbidity and mortality.1,2 Acute
exacerbations of lung disease, when moderate or severe, typi-
cally require intravenous broad-spectrum antibiotics targeted
at the most likely identified pathogens, including Pseudomonas
aeruginosa, Staphylococcus aureus and other more difficult-to-treat
Gram-negative bacteria.3,4 Treatment is typically initiated with
anti-pseudomonal b-lactam antibiotics such as ceftazidime,
piperacillin/tazobactam or meropenem, often in combination
with a second antibiotic targeting P. aeruginosa or an antibiotic
that targets MRSA if suspected.
Antibiotic resistance among Gram-negative bacteria in the CF
population is very common and appears to be increasing.5 – 8 As a
result, few options are available to treat exacerbations associated
with antibiotic-resistant organisms. Previously, it was demon-
strated that standard doses for common intravenous b-lactam
antibiotics resulted in lower than expected pharmacodynamic
exposures in children with and without CF and that administering
these drugs as prolonged (i.e. administered over 3 h) or continu-
ous (i.e. administered over 24 h) infusions improved these expo-
sures.9 – 13 Sub-optimal dosing in a child with CF may lead to
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poor clinical outcomes and the development of multidrug resist-
ance.14 Like other b-lactam antibiotics, prolonging the infusion of
meropenem to 3 h increases the time that free drug concentra-
tions remain above the MIC (fT.MIC), which is the pharmacody-
namic index that best correlates with killing bacteria for the
carbapenem agents.15 The pharmacokinetics of meropenem
have been described in paediatric patients across various
ages.16 – 20 However, despite the common utilization of merope-
nem to treat CF acute pulmonary exacerbations, none of these
studies has included children with CF. Herein, we describe the
population pharmacokinetics, tolerability and feasibility of
prolonged-infusion meropenem in children with CF.
Methods
Study design and patients
This was a prospective, multicentre, open-label pharmacokinetic study in
paediatric CF patients receiving at least three doses of prolonged-infusion
(3 h) meropenem (NCT#01429259) during treatment of a pulmonary
exacerbation. This study was reviewed and approved by the institutional
review board of all participating centres [Hartford Hospital #003498HE,
UNC #4248-12-0198, Drexel (St. Christopher’s Hospital for Children)
#12050534, Columbia University Medical Center #IRB-AAAI6001,
Nationwide Hospital for Children #IRB13-00064, Indiana University (Riley
Hospital for Children) IRB#1212010146, Connecticut Children’s Medical
Center #13-004, Southwestern Texas University (Children’s Hospital)
#012013-018] and informed assent and consent were required of all par-
ticipants and their parents/legal guardians. Eligible patients included chil-
dren with CF aged 6 –17 years who were hospitalized for an acute
pulmonary exacerbation and required treatment with intravenous antibio-
tics as per their treating CF physician. An acute pulmonary exacerbation
was defined using a modification of the Fuchs criteria;21 exacerbations
included at least four signs and symptoms excluding sinus pain or tender-
ness as recommended by the advisory panel of the FDA. In addition, chil-
dren deemed to clinically require intravenous antibiotic therapy by their
treating CF physician were eligible for enrolment. Patients were excluded
if they had known or suspected hypersensitivity to meropenem, concomi-
tant intravenous antibiotic therapy with another b-lactam antibiotic,
known fungal or viral infection, pregnancy, moderate to severe renal dys-
function, solid organ transplant within 6 months or participated in another
antibiotic clinical trial in the previous 30 days.
Antibiotic therapy
Patients received 40 mg/kg meropenem (maximum 2000 mg per dose)
every 8 h with each dose infused as a 3 h infusion. Meropenem was sup-
plied from the participating hospital’s pharmacy department and prepared
in accordance with US prescribing preparation instructions.22 All doses
were prepared either in syringes or infusion bags as per local pharmacy
guidelines and were stored in the refrigerator until administered (within
24 h). Patients received a minimum of three doses of meropenem as pro-
longed infusion, but providers were encouraged to complete the full treat-
ment course (14–21 days) using prolonged infusion. Combination therapy
with an intravenous aminoglycoside, fluoroquinolone or polymyxin anti-
biotic was permitted along with vancomycin or linezolid for MRSA.
Meropenem concentration determination
Blood samples were collected no earlier than after the third dose of
prolonged-infusion meropenem. Four samples per patient were collected
at the following timepoints: 3–3.5, 4–5, 5–6 and 7–8 h after the initiation
of the prolonged infusion, to allow some flexibility with patient care. Actual
sampling times were recorded and used for the pharmacokinetic analyses.
All blood samples were placed on ice for no longer than 5 min and then
immediately centrifuged at 2000 g for 10 min to collect the separated
serum. The serum was divided equally into two cryovials for storage at
2808C until meropenem concentrations were determined at the Center
for Anti-Infective Research and Development (Hartford, CT, USA) using a
previously published validated HPLC assay.23 The inter-day coefficient of
variation for high (30 mg/L) and low (0.5 mg/L) check samples were
5.5% and 4.4%, respectively; intra-day coefficients of variation were
1.6% and 2.1%, respectively.
Pharmacokinetic analyses
Concentration data were modelled using the non-parametric adaptive grid
program (NPAG) with adaptive gamma in the Pmetrics package for R (ver-
sion 1.4.1).24 One- and two-compartment models were differentiated
based on log-likelihood and the Akaike information criterion (AIC).25
Additionally, predictive performance of the final model was based on
the mean weighted predicted–observed error (bias), the bias-adjusted,
mean weighted squared predicted–observed error (imprecision) and
weighted residual plots. A multiplicative assay variance model was deter-
mined by fitting a polynomial to the plot of the inter-day assay standard
deviation versus the measured meropenem concentrations, generating
the following formula: SD¼g×(0.00761+0.0392×C), where C is merope-
nem concentration and g represents all environmental variability exclud-
ing the assay. Once the base model was established, linear regression
(Sigma Plot Version 12.0, Systat, Chicago, IL, USA) was used to characterize
the relationship between clearance and volume of distribution parameters
and patient covariates [age (years), height (cm), weight (kg), serum cre-
atinine (mg/dL), glomerular filtration rate (GFR) (mL/min) as estimated
by the Schwartz et al.26 equation, BMI (kg/m2), body surface area (m2)
and lean body weight (kg) estimated as described by Peters et al.27].
Covariates that were statistically significant were then incorporated back
into the population model and tested for model superiority by further
reductions in AIC. Body size covariates were tested proportionally to clear-
ance and volume of distribution as well as by allometric scaling.28
Monte Carlo simulation
A 5000-patient Monte Carlo simulation was conducted using the simulator
in Pmetrics for meropenem dosage regimens of 40 mg/kg every 8 h as 0.5
and 3 h infusions. Concentrations were simulated at 15 min intervals for
six doses. The mean, standard deviation and range for the weight of the
participants were used as the simulated population. During simulation,
Pmetrics will rebuild a covariance matrix that includes the pharmacoki-
netic parameters and included covariates, so that these are sampled con-
sistent with their relationships. Probability of pharmacodynamic target
attainment (PTA) was assessed over a range of MICs between 0.03 and
128 mg/L in doubling dilutions. The pharmacodynamic index targeted
was an fT.MIC ≥40% of the dosing interval.15 The fraction unbound for
meropenem was fixed at 0.98.22 An a priori PTA of ≥95% was considered
optimal.29 For comparison, the concentration–time profiles for the 30 par-
ticipants were re-simulated based on the identified individual posterior
pharmacokinetic parameter estimates and the actual dosing regimen
and timings received for the first 24 h. Concentrations were corrected for
the fraction unbound as above and the mean, SD and PTA were calculated
at MICs of 2, 4 and 8 mg/L.
Feasibility, safety and treatment burden
The safety and tolerability of prolonged-infusion meropenem were
assessed throughout the treatment course until the end of therapy
assessment, performed within 7 days of the last meropenem prolonged-
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reported by the patient and any clinically significant changes in physical
examination or laboratory values (chemistry, haematology, liver function
tests) between baseline and completion of therapy. Feasibility was
assessed by quantifying the percentage of patients completing antibiotic
therapy with the prolonged-infusion regimen in and outside of the hos-
pital. Treatment burden was quantified by administering the Cystic
Fibrosis Questionnaire-Revised (CFQ-R) before and after the prolonged-
infusion meropenem therapy.30 Age-appropriate versions of the CFQ-R
were used for children (6–11 years of age, administered by study coordin-
ator to caregiver; 12–13 years of age, self-reported) and adolescents
(≥14 years of age, self-reported) participating in the study. These data
were analysed qualitatively for conclusions about the burden of prolonged
infusion. A minimally clinically significant difference was defined as a
change of 4 points in the treatment burden domain.31
Results
Participants
Thirty children were enrolled and completed the pharmacokinetic
study. Demographic and clinical characteristics, including body
weight parameters used for the Monte Carlo simulation, are
provided in Table 1. The bacteria isolated from participants
included P. aeruginosa (n¼18/30 patients, 60%), S. aureus
[n¼18/30, 60%; 8/18 (44%) were MRSA], Stenotrophomonas
maltophilia (n¼5/30, 17%), Achromobacter xylosoxidans (n¼1/30,
3%), Enterobacter cloacae (n¼1/30, 3%), Citrobacter freundii
complex (n¼1/30, 3%) and Inquilinus limosus (n¼1/30, 3%).
Four (13%) participants had no bacteria isolated at baseline.
Meropenem pharmacokinetics
The two-compartment model fitted the data best, as determined
by a smaller AIC score of 122.74 versus 405.73 for the one-
compartment model. Among tested covariates, only body weight
(kg), lean body weight (kg), height (cm) and body surface area
(m2) were significantly associated with meropenem clearance
and/or volume of the central compartment (Vc). A detailed
description of the covariate model selection and the final
weighted residual plot can be found in the Supplementary data
available at JAC Online (http://jac.oxfordjournals.org/). The final
model produced an AIC of 100.37 and estimated clearance as a
ratio of body weight (CL¼CL0×weight) and Vc by linear allometric
scaling (Vc¼Vc0×weight/40.9). The final parameter estimates
from the population model are presented in Table 2. The final
mean+SD values for clearance and Vc among these 30 partici-
pants were 16.14+9.25 L/h and 11.57+5.60 L, respectively.
Corrected for body weight, these values were 0.41+0.23 L/h/kg
and 0.30+0.17 L/kg, respectively. The final estimate for g was
0.755, indicating little environmental variability. The observed versus
population-predicted meropenem concentration and the observed
versus individual-predicted meropenem concentration are pro-
vided in Figures 1 and 2, respectively.
Monte Carlo simulation
The PTA results for 40 mg/kg meropenem every 8 h simulated as
0.5 and 3 h infusions are displayed in Figure 3. The simulated
prolonged-infusion regimen achieved greater PTA compared
with the 0.5 h standard infusion at MICs of 0.5, 1, 2, 4, 8 and
16 mg/L. Optimal PTA was achieved for the standard infusion for
MICs ≤0.25 mg/L while the prolonged-infusion regimen achieved
optimal PTA for MICs ≤4 mg/L.
For the 30 individual participants, the mean+SD fT.MIC for
their prolonged-infusion regimen of 40 mg/kg every 8 h was
72.8+10.6%, 61.4+8.8% and 49.4+9.4% at MICs of 2, 4 and
8 mg/L, respectively. This corresponded with actual PTAs of
100%, 100% and 90%, respectively.
Feasibility, safety and treatment burden
Prolonged-infusion meropenem was well tolerated in this study,
with only one patient discontinuing therapy because of an
adverse event. Adverse effects were reported in 8 participants
and included leucocytosis (n¼1), thrombocythaemia (n¼1),
Table 2. Final population pharmacokinetic parameter estimates for 30
children with CF receiving prolonged-infusion meropenem
Mean SD Median
Model-derived pharmacokinetic parameters
CL0 (L/h/kg) 0.41 0.23 0.37
Vc0 (L) 12.29 6.79 12.31
Kcp (h
21) 0.738 1.165 0.195
Kpc (h
21) 1.71 1.598 0.950
Calculated pharmacokinetic parameters
CL (L/h), CL¼CL0×body weight in kg 16.14 9.25 14.31
Vc (L), Vc¼Vc0×body weight in kg/40.9 11.57 5.60 9.88
Vc (L/kg) 0.30 0.17 0.30
Vss (L/kg) 0.43 0.34 0.38
half-life (h) 1.11 0.38 1.00
CL0, clearance; Vc0, allometric volume of distribution of the central
compartment; Kcp, microtransfer rate constant from the central
compartment to the peripheral compartment; Kpc, microtransfer rate
constant from the peripheral compartment to the central compartment;
CL, clearance; Vc, volume of distribution of the central compartment, Vss,
total volume of distribution at steady state.
Table 1. Baseline demographic and clinical characteristics of 30 children
with CF receiving prolonged-infusion meropenem
Characteristic
Age (years), mean+SD (range) 12.7+2.9 (8–17)
Weight (kg), mean+SD (range) 40.9+12.2 (20.4–68.2)
Lean body weighta (kg), mean+SD (range) 33.8+9.1 (19.0–54.4)
Height (cm), mean+SD (range) 149+17 (123–183)
BMI (kg/m2), mean+SD (range) 18.0+2.6 (11.9–24.8)
Male, n (%) 14 (47)
GFRb (mL/min/1.73 m2), mean+SD (range) 162+34 (97–229)
Baseline FEV1 (% predicted), mean+SD (range) 58+24 (18–126)
Historical best FEV1 (% predicted),
mean+SD (range)
71+25 (23–123)
Fuchs criteria fulfilled, n (%) 23 (77)
aCalculated by the Peters et al.27 method.
bCalculated by the Schwartz et al.26 method.
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rash (n¼2), fever (n¼2), elevated C-reactive protein (n¼3),
Clostridium difficile infection (n¼2), pancytopenia (n¼1), ele-
vated liver function tests (n¼2) and hyperbilirubinaemia (n¼1).
Participants received a mean+SD of 32+16 meropenem
doses as 3 h infusions during the study, of which 28+16 were
received in the hospital. The median meropenem treatment dur-
ation was 14 (IQR 11–20) days. Eighteen of the 30 participants
(60%) completed their entire course of antibiotic treatment with
prolonged-infusion meropenem. Among these 18 participants, 13
(72%) completed their course within the hospital and 5 (28%)
were discharged to complete prolonged infusion at home. An
additional nine participants (30%) completed antibiotic treat-
ment with meropenem, but had therapy modified to a 0.5 h infu-
sion when discharged home. Three additional participants (10%)
had modification of their antimicrobial therapy while in the hos-
pital due to adverse events (n¼1) or lack of response (n¼2).
No participants had prolonged infusion discontinued in the
hospital setting due to feasibility concerns. Among the five parti-
cipants completing prolonged-infusion meropenem at home,
none of their families reported a burden. In contrast, the families
of the nine participants who chose to receive 0.5 h infusions at
home reported doing so because of a perceived burden from
using 3 h infusions that would interfere with school attendance,
care of other children or both. The CFQ-R was completed (pre-
and post-meropenem treatment) by 11 children (6 –13 years
old), 12 adolescents and 11 caregivers. Among the children/care-
givers, data for nine participants were completed by both.
Treatment burden scores for the 11 children were 63.6+19.3
and 62.6+27.8 at pre- and post-meropenem evaluations,
respectively. Treatment burden scores for the 12 adolescents
were 48.6+21.9 and 46.3+21.6 at pre- and post-meropenem
evaluations, respectively. Finally, treatment burden scores for
the 11 caregivers were 45.0+17.7 and 34.3+16.8 at pre- and
post-meropenem evaluations, respectively. The caregivers were
the only group reporting an increase in treatment burden after
the prolonged-infusion meropenem, as noted by a reduction in
score by ≥4 points.
Discussion
In the USA, meropenem is one of a few anti-pseudomonal
b-lactam antibiotics routinely prescribed for the treatment of
acute pulmonary exacerbations in CF children.32 Despite this com-
















Inter = 0.13 (95%CI –0.0215 to 0.281)





Figure 2. Observed versus MAP Bayesian individual-predicted (using
median population parameter estimates) meropenem concentrations.
The continuous line is the regression line and the broken line is the line
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Figure 1. Observed versus population-predicted (using median parameter
estimates) meropenem concentrations (mg/L) for the final model. The
continuous line is the regression line and the broken line is the line of unity.
0
0.03 0.06 0.125
40 mg/kg every 8 h (0.5 h infusion)
40 mg/kg every 8 h (3 h infusion)
0.25 0.5 1 2
MIC (mg/L)















Figure 3. PTA at each MIC for 40 mg/kg meropenem every 8 h regimens
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determined in children with CF, a population that is known to elim-
inate some antibiotics more rapidly than non-CF patients.33 – 35
Additionally, pharmacokinetic data from adult patients with CF
suggest that administering meropenem as prolonged or continu-
ous infusions effectively increases the fT.MIC and enables treat-
ment of exacerbations associated with organisms with higher
MICs.36 – 38 In the current study, meropenem was administered
as a 3 h prolonged infusion to 30 children with CF who were
admitted for a pulmonary exacerbation to determine pharmaco-
kinetics, tolerability, feasibility and treatment burden.
Increased total body clearance of renally eliminated drugs in
CF patients is thought to be due to increased GFR secondary to
a primary tubular transport defect or higher resting energy
expenditure.39,40 We observed that the clearance of meropenem
in these children, when scaled to body weight, was slightly greater
compared with values reported from non-CF children. Meropenem
clearance in this study was 0.41+0.23 L/h/kg (median 0.37 L/h/kg)
and ranged from 0.17 to 1.36 L/h/kg. As identified in many
paediatric meropenem pharmacokinetic studies,16 – 20 weight
was a significant covariate of total body clearance. During our
modelling, the addition of body weight as proportional to clear-
ance (CL¼CL0×body weight in kg) significantly improved the fit
of the model over that of allometric scaling or assessment of
other tested body size descriptors (i.e. lean body weight, height)
(see Supplementary data available at JAC Online). Our estimates
of clearance were greater than that of Du et al.,17 who deter-
mined the population pharmacokinetics in non-CF children aged
0.08–17 years (mean weight 16.8 kg) and observed a mean
clearance of 0.33+0.09 L/h/kg. Our observations are also greater
than the clearance observed in 40 non-CF Japanese children aged
0.2–14 years (mean weight 23 kg), reported at0.34 L/h/kg.20 In
contrast, half-life as estimated by the beta terminal elimination
phase was largely similar (1.1 h) to that of non-CF children
(1.3 h).17 Notably, GFRs, as calculated by the Schwartz et al.26
method, were not significantly associated with clearance in this
study. This is different from other paediatric meropenem studies,
where creatinine clearance was an important covariate of clear-
ance;17 however, all of the CF participants in the current study
had relatively high GFR at baseline, which may have prevented
any observation of a significant relationship. In the absence of
standard therapeutic drug monitoring for meropenem, further
research is needed to identify patient factors that may be predict-
ive of increased clearance and low concentrations.
One in every four CF patients experiencing a pulmonary exacer-
bation do not recover to their baseline forced expiratory volume in
1 s (FEV1) after treatment.
41 As lung function decline has signifi-
cant morbidity and mortality for CF patients, it is prudent to opti-
mize the treatment of these exacerbations, including proper
dosing of antibiotics. This is increasingly important in patients
with CF, given the higher rates of antibiotic-resistant bacteria.8
It is well established that b-lactam antibiotics kill bacteria best
when their concentrations are maintained above their MIC for a
given percentage of the dosing interval.15 Murine infection models
have confirmed these observations for meropenem, identifying
40% fT.MIC as the maximum bactericidal exposure during 24 h
experiments.15 Unfortunately, these studies have not been con-
ducted in the CF population, so we must assume that the pharma-
codynamic index is similar between CF and non-CF patients. Using
this exposure as the threshold, the Monte Carlo simulation
showed that a standard dosing regimen of 40 mg/kg every 8 h
infused over 0.5 h would not achieve optimal PTA once the MIC
was above 0.5 mg/L (Figure 3). Of note, P. aeruginosa susceptibility
to meropenem is defined by CLSI as an MIC≤2 mg/L, while 4 mg/L
defines intermediate susceptibility and ≥8 mg/L denotes resist-
ance.42 Breakpoints defined by EUCAST are ≤2 mg/L for suscep-
tible and .8 mg/L for resistant.43 We found that prolonging the
infusion to 3 h during the simulation resulted in nearly 100%
attainment of the 40% exposure threshold for MICs ≤4 mg/L.
Furthermore, the prolonged infusion was also able to achieve
40% fT.MIC in 82.8% of simulated patients at an MIC of 8 mg/L,
suggesting that this regimen could provide empirical exposure
for some non-susceptible P. aeruginosa provided the MIC is not
greater than 8 mg/L. These values were in agreement with the
actual PTAs achieved by the 30 participants over the first 24 h of
exposure (i.e. 100%, 100% and 90% at MICs of 2, 4 and 8 mg/L,
respectively) and are also in agreement with studies in non-CF
children and adults.10,15,44 It is also worth mentioning that
although meropenem could be administered as a continuous infu-
sion,36 its short room-temperature stability of 4–6 h makes the
3 h prolonged-infusion regimen particularly attractive.15
Prolonged-infusion meropenem was overall well tolerated in
the study. The adverse effects observed were those already
reported in the meropenem package insert with the standard
infusion time.22 No adverse events were specifically reported
due to the prolonged infusion. One critical consideration regarding
the prolonged-infusion regimen is the impact on the quality of life
of CF patients. CF care creates a substantial treatment burden;
however, the children and adolescents completing the CFQ-R in
this study did not report any change in treatment burden after
receiving the prolonged-infusion regimen. Notably, there was a
change in treatment burden scores for the caregivers. Our obser-
vations indicate that it is feasible to incorporate prolonged-
infusion meropenem during inpatient hospitalization. However,
prolonged infusion during home intravenous therapy may be
more difficult to incorporate into daily life, especially among
school-age children. Despite this perception, two crossover design
studies have compared ceftazidime continuous infusion versus
intermittent infusion three times a day in paediatric patients in
the home setting. These studies found no difference in quality of
life scores; moreover, 82% of patients preferred the continuous-
infusion regimen in one study.45,46 In our study, patients were
given the option of receiving the prolonged infusion at home
and five patients successfully completed prolonged infusion in
this setting with no reported treatment burden. The nine patients
that elected to complete therapy at home with the 0.5 h infusion
reported doing so because of the perceived burden that prolonged
infusions would interfere with school attendance, care of other
children or both. Additional studies are needed to clarify the role
and potential value of prolonged infusion in the home setting.
This study has some limitations. The study was not designed to
assess clinical outcome; therefore, no control was included. Only
30 participants were included, which, although reasonable for
determining pharmacokinetics in a population, may have pre-
vented us from identifying any characteristics that could predict
patient outliers and low meropenem concentrations. The small
sample size limited assessment of treatment burden, our second-
ary outcome measure, especially since not all participants com-
pleted the CFQ-R and only 5 of the 14 patients who completed
intravenous therapy at home received the prolonged infusion in
that setting. However, nearly all patients (n¼13/16) completing
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antibiotics in the hospital remained on the prolonged-infusion
regimen. These patients may have been sicker or have had organ-
isms that were more difficult to treat, and are an important target
population. Nonetheless, these promising observations, coupled
with the pharmacokinetic and Monte Carlo simulation results, jus-
tify future studies comparing standard and prolonged-infusion
regimens.
Conclusions
To our knowledge, this is the first pharmacokinetic study of
prolonged-infusion meropenem in children with CF. The data sug-
gest some differences in meropenem pharmacokinetics com-
pared with non-CF children, notably more rapid total body
clearance, which could result in lower meropenem concentra-
tions. Considering this, prolonged-infusion meropenem provided
a greater likelihood of obtaining 40% fT.MIC against pathogens
with meropenem MICs of 1–8 mg/L. Prolonged-infusion merope-
nem was well tolerated and feasible to administer in the hospital
and home settings, the latter depending on perception and family
schedule.
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